Exodus Point Capital Management, LP Prelude Therapeutics Inc Transaction History
Exodus Point Capital Management, LP
- $16.4 Billion
- Q3 2024
A detailed history of Exodus Point Capital Management, LP transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Exodus Point Capital Management, LP holds 921,621 shares of PRLD stock, worth $829,458. This represents 0.01% of its overall portfolio holdings.
Number of Shares
921,621Holding current value
$829,458% of portfolio
0.01%Shares
5 transactions
Others Institutions Holding PRLD
# of Institutions
71Shares Held
35.7MCall Options Held
500Put Options Held
300-
Orbimed Advisors LLC San Diego, CA10.9MShares$9.82 Million0.53% of portfolio
-
Baker Bros. Advisors LP New York, NY10.1MShares$9.11 Million0.22% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.77MShares$3.39 Million0.14% of portfolio
-
Boxer Capital, LLC San Diego, CA1.71MShares$1.54 Million0.19% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.1MShares$987,8390.0% of portfolio
About Prelude Therapeutics Inc
- Ticker PRLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,369,200
- Market Cap $32.7M
- Description
- Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...